All AbMole products are for research use only, cannot be used for human consumption.
AZD3514 is a potent, orally activie and selective androgen receptor (AR) inhibitor with potential anticancer cancer activity. AZD3514 binds to the AR ligand binding domain and has selectivity for binding to AR over other nuclear hormone receptors.
AZD3514 has been shown to reduce AR protein expression, PSA synthesis and cell growth in vitro in a subclone of cells serially maintained in the presence of bicalutamide (LNCaP-CR). AZD3514 (0-30 μM/L; 24 h) reduces AR protein expression in LNCaPs and LAPC4s.
In vivo, oral dosing of AZD3514 (100mg/kg once-daily for 7 days) significantly inhibited testosterone-induced growth of sexual accessory organs in the Hershberger castrated rat assay. AZD3514 treatment also reduced AR protein in LNCaP cells maintained in steroid-depleted conditions; an effect which was evident within 6 - 8h, and maximal at 18 - 24h. Administration of AZD3514 (100 mg/kg/day orally) for 3 days to Copenhagen rats bearing R3327H Dunning prostate tumours, indicates that AZD3514 treatment also reduces tumour AR in vivo.
| Molecular Weight | 519.56 |
| Formula | C25H32F3N7O2 |
| CAS Number | 1240299-33-5 |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Androgen Receptor Products |
|---|
| LGD-3303
LGD-3303 is a nonsteroidal, nonaromatizable selective androgen receptor ligand that binds to the androgen receptor with high affinity in a radiolabeled to competitive binding assay (Ki=0.9 nM). |
| Ar-V7-IN-1
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications such as prostate cancer. |
| SC912
SC912 is a potent and selective AR-V7 inhibitor with IC50 of 0.36 μM. SC912 binds directly to AR-FL and AR-V7 proteins, inhibites nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis. |
| A4B17
A4B17 is an androgen receptor N-terminal inhibitor, which can be used for the research of androgen-responsive prostate cancer. |
| AZ'3137
AZ‘3137 is an orally active PROTAC-type androgen receptor (AR) degrader, with a DC50 value of 22 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
